Botulinum toxin prefilled glass syringe

1. A prefilled glass syringe comprising an aqueous botulinum toxin formulation, the glass syringe comprising

(a) a syringe barrel made of glass including a proximal end and a distal end, and a cylindrical wall extending therebetween and defining a barrel lumen, the syringe barrel having a distally projecting tip with a fluid passage extending therethrough and communicating with the barrel lumen, wherein the cylindrical wall has an interior surface optionally coated with a barrier layer,

(b) a capping device having an outlet engaging portion sealingly engaging and closing the distal open outlet end of the syringe, wherein the outlet engaging portion is made of an elastomeric material that optionally has a coating on its surface, and

(c) a plunger rod assembly which extends into the proximal end of the syringe barrel and includes a plunger stopper in sliding fluid-tight engagement with the cylindrical wall of the barrel lumen, wherein the plunger stopper is made of an elastomeric material, which optionally has a coating on at least a portion of the plunger stopper that contacts the aqueous botulinum toxin formulation during storage and/or injection,

wherein the elastomeric material of the outlet engaging portion is selected from the group consisting of isoprene rubber, butadiene rubber, butyl rubber, halogenated butyl rubber, styrene-butadiene rubber, and mixtures thereof, and

the elastomeric material of the plunger stopper is selected from the group consisting of isoprene rubber, butadiene rubber, butyl rubber, halogenated butyl rubbers, styrene-butadiene rubber, and mixtures thereof, and

wherein the toxin activity is not reduced by more than 25%, relative to the initial toxin activity, upon storage of the prefilled glass syringe for 12 months at 5° C. or 12 months at 25° C.

2. The prefilled glass syringe of claim 1 , wherein the number of subvisible particles of equal to or greater than 10 μm is below 1000/ml during storage for 6 to 24 months at 2° C. to 30° C.

3. The prefilled glass syringe of claim 1 , wherein the pH value is not increased or decreased by more than 10%, relative to the initial pH value, upon storage of the prefilled glass syringe for 6 to 12 months at 5° C. or 25° C., or wherein the pH of the aqueous botulinum toxin formulation during storage is maintained in the range of 6.0 to 7.5, or both.

4. The prefilled glass syringe of claim 1 , wherein the botulinum toxin is present in the aqueous formulation at a concentration of 10 U/ml to 1000 U/ml.

5. The prefilled glass syringe of claim 1 , wherein the aqueous botulinum toxin formulation in the prefilled glass syringe does not contain a buffer.

6. The prefilled glass syringe of claim 1 , wherein the optional coating on the outlet engaging portion is present and is a crosslinked silicone coating or a fluoropolymer coating.

7. The prefilled glass syringe of claim 1 , wherein the barrier layer of the syringe barrel is present and is a silicone-free layer or a silicone layer.

8. A kit comprising a prefilled glass syringe according to claim 1 and, optionally, instructions for use of said prefilled glass syringe.

9. A method of treating a disease or condition caused by or associated with hyperactive cholinergic innervation of muscles or exocrine glands in a patient, the method comprising locally administering an effective amount of botulinum toxin to a muscle or exocrine gland of the patient by injection using the prefilled glass syringe according to claim 1 .

10. A method for the cosmetic treatment of the skin, optionally for treating wrinkles of the skin and facial asymmetries, the method comprising locally administering an effective amount of botulinum toxin to a patient by intradermal, subdermal or subcutaneous injection using the prefilled glass syringe according to claim 1 .

11. The prefilled glass syringe of claim 1 , wherein the optional coating on the plunger stopper is present and is a crosslinked silicone coating or a fluoropolymer coating.

12. The method of claim 9 , wherein the disease or condition caused by or associated with hyperactive cholinergic innervation of muscles or exocrine glands is selected from dystonia, spasticity, paratonia, diskinesia, focal spasm, strabismus, tremor, tics, migraine, sialorrhea and hyperhidrosis.

13. The prefilled glass syringe of claim 1 , wherein the toxin activity is not reduced by more than 25%, relative to the initial toxin activity, upon storage of the prefilled glass syringe for 12 months at 5° C.

14. The prefilled glass syringe of claim 1 , wherein the toxin activity is not reduced by more than 25%, relative to the initial toxin activity, upon storage of the prefilled glass syringe for 12 months at 25° C.

15. A kit according to claim 8 , comprising instructions for use of said prefilled glass syringe.

16. A method according to claim 10 , comprising treating wrinkles of the skin and facial asymmetries.